SGMT · XBRL financial data

Sagimet Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SGMT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	2,000	0*	—	—	—	—	—	—	—	—	—	—
Research and development	4,958	5,656*	5,262	6,313	12,653	14,216*	15,342	7,248	9,730	6,734*	6,995	11,535
General and administrative	4,494	3,810*	3,506	4,276	4,249	3,979*	4,523	4,677	4,604	4,031*	4,718	4,283
Total operating expenses	9,452	9,466*	8,768	10,589	16,902	18,195*	19,865	11,925	14,334	10,765*	11,713	15,818
Operating income (loss)	(7,452)	(9,466)*	(8,768)	(10,589)	(16,902)	(18,195)*	(19,865)	(11,925)	(14,334)	(10,765)*	(11,713)	(15,818)
Other income (expense)	1,099	1,315*	2,139	2,471	2,283	1,994*	1,689	1,539	1,426	1,197*	1,063	1,865
Income tax expense (benefit)	—	—	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(6,353)	(8,151)*	(6,629)	(8,118)	(14,619)	(16,201)*	(18,176)	(10,386)	(12,908)	(9,568)*	(10,650)	(13,953)
Earnings per share, basic USD per share	(0.35)	—	(0.23)	(0.25)	(0.45)	(0.50)*	(0.56)	(0.32)	(0.40)	(0.29)*	(0.33)	(0.26)
Earnings per share, diluted USD per share	(0.35)	—	(0.23)	(0.25)	(0.45)	(0.50)*	(0.56)	(0.32)	(0.40)	(0.29)*	(0.33)	(0.26)
Weighted average shares, basic thousands of shares	18,195	—	29,039	31,914	32,143	32,287*	32,195	32,195	32,465	32,522*	32,560	53,115
Weighted average shares, diluted thousands of shares	18,195	—	29,039	31,914	32,143	32,287*	32,195	32,195	32,465	32,522*	32,560	53,115

Balance sheet

CSV

Fiscal quarters (SGMT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	101,842	75,139	176,777	95,959	77,014	75,840	64,717	42,327	32,496	35,021	36,626	165,896
Marketable securities	0	19,758	16,928	70,414	75,472	75,410	79,852	83,080	84,197	78,103	67,913	74,232
Marketable securities, non-current	—	—	—	22,118	17,471	7,408	—	10,059	8,806	0	—	17,436
Prepaid and other current assets	974	1,749	786	378	4,704	1,524	1,503	1,789	2,787	3,280	3,177	3,860
Total current assets	102,816	96,646	194,491	166,751	157,190	152,774	146,072	127,196	119,480	116,404	107,716	243,988
Right-of-use asset	109	73	37	151	114	77	38	152	115	78	39	1,951
Total assets	102,925	96,719	194,528	189,020	174,775	160,259	146,172	137,407	128,401	116,482	107,755	263,430
Accounts payable	1,702	186	531	1,994	1,152	1,425	3,223	1,921	4,243	1,309	2,303	1,131
Accrued liabilities	3,244	5,403	3,953	3,581	2,824	2,951	3,918	5,174	4,788	3,714	2,955	4,204
Total current liabilities	5,049	5,654	—	—	—	4,454	—	7,247	9,146	5,101	5,297	5,419
Lease liability, non-current	—	—	—	—	—	—	—	—	—	0	—	1,856
Total liabilities	5,050	5,654	4,510	5,728	4,092	4,454	7,180	—	—	5,101	—	7,275
Accumulated deficit	(241,593)	(249,744)	(256,373)	(264,491)	(279,110)	(295,311)	(313,487)	(323,873)	(336,781)	(346,349)	(356,999)	(370,952)
Total stockholders' equity	97,875	91,065	190,018	183,292	170,683	155,805	138,992	130,160	119,255	111,381	102,458	256,155
Total liabilities and equity	102,925	96,719	194,528	189,020	174,775	160,259	146,172	137,407	128,401	116,482	107,755	263,430
Common shares outstanding (cover page) thousands of shares	21,375	0	30,393	30,675	30,675	—	—	—	—	—	—	—

Cash flows

CSV

Fiscal quarters (SGMT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6,353)	(8,151)*	(6,629)	(8,118)	(14,619)	(16,201)*	(18,176)	(10,386)	(12,908)	(9,568)*	(10,650)	(13,953)
Stock-based compensation	1,855*	1,311*	759	1,449*	1,546*	1,534*	1,472	1,598*	1,688*	1,691*	1,839	3,691*
Net cash from operating activities	(3,879)*	(7,083)*	(6,208)	(5,634)*	(19,569)*	(11,024)*	(14,536)	(9,101)*	(10,180)*	(11,833)*	(8,611)	(11,099)*
Net cash from investing activities	0*	(19,620)*	3,000	(75,157)*	624*	9,850*	3,413	(13,290)*	75*	14,358*	10,216	(24,020)*
Proceeds from issuing common stock	—	—	105,750	0*	0*	0*	—	—	0*	0*	—	—
Net cash from financing activities	87,213*	0*	104,846	(27)*	0*	0*	—	—	274*	0*	—	—

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	17,241	not reported	(2,189)*	37.9M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	16,329	54,978	(17,809)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138,343	not reported	(7,588)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.